Asenapine for Bipolar Depression

Bipolar Depression Clinical Trial

Official title:

Asenapine for Bipolar Depression

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01807741
• Other study ID #: 2012-4181
• Status: Terminated
• Phase: Phase 2
• First received: March 6, 2013
• Last updated: July 20, 2017
• Start date: September 2013
• Est. completion date: July 2017

Study information

• Verified date: July 2017
• Source: University of Cincinnati
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare asenapine with placebo in the treatment of depression associated with bipolar disorder, type I over eight weeks.

We hypothesize that patients will show significantly greater improvement with asenapine than placebo over eight weeks of treatment.

Description:

86 patients with an episode of major depression associated with bipolar disorder, type I will be recruited by two sites for the study over fifteen months. Medication will be administered in a double-blind manner. Patients will receive asenapine (or placebo) beginning on day 0 at 5 mg bid. Dose may be increased to 10 mg bid and adjusted based on clinical response. Patients will be evaluated by a blinded (to treatment status) rater. Patients will be seen and ratings obtained at baseline (day 0) and on days 7, 14, 28, 42, and 56 (or termination from the study). Adverse events will be evaluated as well.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 51
• Est. completion date: July 2017
• Est. primary completion date: July 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Meet criteria for bipolar depression based on the MINI and confirmation of a previous manic or mixed episode

• 18-55 years of age

• Female patients must be using a medically accepted means of contraception (e.g. oral contraceptives, Depo-Provera, abstinence)

• Each patient must understand the nature of the study and must provide written informed consent

• Patients must have a diagnosis of bipolar disorder, type I and currently display an acute depressive episode as determined by M.I.N.I. (Sheehan et al, 1998)

• Patients must have a baseline (day 0) MADRS score =26

• Current episode of depression must have persisted for at least one month and no more than six months at study entry

• Subjects should be fluent in English

Exclusion Criteria:

• Female patients who are either pregnant or lactating

• Clinically significant or unstable hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, immunologic, hematologic or other systemic medical conditions

• Any history of current or past diabetes that was treated with pharmacological intervention

• Neurological disorders including epilepsy, stroke, or severe head trauma

• Clinically significant laboratory abnormalities, on any of the following tests: CBC with differential, electrolytes, BUN, creatinine, hepatic transaminases, lipid profile, fasting glucose, urinalysis, thyroid indices and EKG

• Depression due to a general medical condition or substance-induced depression (DSM-IV)

• Mental retardation (IQ <70)

• Meeting criteria for a mixed episode, as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)

• History of hypersensitivity to or intolerance of asenapine

• Prior history of asenapine non-response

• DSM-IV substance (except nicotine or caffeine) dependence within the past 3 months

• Judged clinically to be at suicidal risk (defined as having active suicidal ideation, intent or plan, or a serious suicide attempt within 30 days, or a baseline MADRS suicide score of >4)

• Participation in a clinical trial of another investigational drug within 1 month (30 days) prior to study entry

• Failure of the current depressive episode to respond to two or more pharmacological interventions

• Treatment with an injectable depot neuroleptic within less than one dosing interval between depot neuroleptic injections and day 0

• Schizophrenia or other psychotic disorders (including schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to a general medical condition, substance-induced psychotic disorder, psychotic disorder not otherwise specified) as defined in the DSM-IV

• Major depressive disorder, dysthymic disorder, depressive disorder not otherwise specified

Related Conditions & MeSH terms

• Bipolar Depression
• Bipolar Disorder
• Depression
• Depressive Disorder

Intervention

Drug:
• Asenapine
Available in 5 and 10 mg.
• Placebo

Locations

Country	Name	City	State
United States	University of Cincinnati	Cincinnati	Ohio

Sponsors (3)

Lead Sponsor	Collaborator
University of Cincinnati	Merck Sharp & Dohme Corp., University of Louisville

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Depression Score	The Montgomery-Asberg Depression Rating Scale (MADRS)will be used as a measure of efficacy reflecting change in MADRS total scores from baseline to endpoint over 8 weeks.	8 weeks
Secondary	Change in Depression Response Rate	MADRS Response Rate: Defined by a = 50% decrease from baseline to endpoint in MADRS total score over 8 weeks.	8 weeks